BioBlast Pharma (ORPN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Roth Capital Affirms BioBlast Pharma (ORPN) at 'Buy'; Sees Trehalose Plan Heading in Right Direction
August 25, 2016 11:13 AM EDTRoth Capital affirms BioBlast Pharma (Nasdaq: ORPN) with a Buy rating and $15 price target following Q2 results released earlier Thursday.
Analyst Joseph Pantginis commented, ORPN has made important strategic decisions in order to manage cash burn and focus on its lead clinical opportunity with trehalose. To this end, work has been postponed on the mitochondrial protein replacement and readthrough platforms. Regarding trehalose,... More
